comlb
Lieutenant
Posts: 68
|
Pfizer
Jan 19, 2024 3:20:42 GMT
Post by comlb on Jan 19, 2024 3:20:42 GMT
dividend almost 6%, anyone interested yet? any thoughts from our resident pharma expert kathiel ?
|
|
|
Pfizer
Jan 19, 2024 14:30:21 GMT
Post by win1177 on Jan 19, 2024 14:30:21 GMT
dividend almost 6%, anyone interested yet? any thoughts from our resident pharma expert kathiel ? I’m watching Pfizer, pretty strong pharma company that is down temporarily due to lack of recent “blockbuster” drugs, decline in COVID vaccinations/ treatment/ etc. Profitable, but still seen as a “slow growth old pharma company” by many. Dividend of nearly 6%, close to yearly low of $25.76 make it a good buy here, IMHO. Morningstar has cut fair value to $42 per share due to lowered forward guidance. Setting another “low ball” order of $26 to see if I can add a little more to our position of 1.1% of portfolio. Win
|
|
|
Post by steadyeddy on Jan 19, 2024 17:20:12 GMT
I heard that patent cliff (expiring patents) is the main worry with PFE.
|
|
|
Post by kathiel on Jan 19, 2024 17:24:10 GMT
I recommended PFE a couple of months ago when the price was even lower. Like win1177, I've put in low ball orders for some more.
|
|
|
Post by anitya on Jan 19, 2024 20:13:01 GMT
I already have a full position in this but will add more if it gets down to $27 or lower but I do not think it is going there without a catalyst.
|
|
|
Pfizer
Feb 6, 2024 21:21:40 GMT
Post by anitya on Feb 6, 2024 21:21:40 GMT
Bought more earlier this morning. I breakeven now with today's rise in price, including div (6+%) from Jan. I am reinvesting dividends.
I am overweight in PFE which also pushes my HC allocation to over, over weight - not by design.
|
|
|
Post by bb2 on Mar 5, 2024 21:16:59 GMT
RE PFE Seagen buy for $43B for $10B in estimated sales by 2030.
I just read Walter Isaacson's "The Code Breaker" on the development of CRISPR technology and became excited about genetic engineering. (Spent much more time googling about biology and genetic engineering than reading the book.) Also been reading about antibody drug conjugates, ADCs, which is what Seagen specializes in and which are under continued development. I bet there are many university labs working on improving ADCs and an important innovation could come from anywhere at any time. (BMY put $100M, up to $180M, into Orum, a company which came up with a new ADC recently, targeted protein degradation, basically a field in itself.) Thinking PFE has a lot of competition though maybe they have the chops - they did impress during the pandemic. It's so interesting how all these ideas build on previous ones. "standing on the shoulders of giants".
I'm holding PFE and don't feel it's cheap just because it's below its pre-pandemic levels. Decent div safety at least. I'll in at $24; maybe sooner if I change my mind.
I should add that I get Josh Brown's free email, (is is mostly marketing), and he just bought PFE on the thesis that it's an old company that's not going anywhere and it must be at worst 20% above the bottom. Div not bad either.
It just occurred to me that my brilliant analysis of Nvidia a few years back when their rev growth was negative, was WAY off. ("How hard can it be to design a chip? I've programmed these things and what's NVDA have that others can't do better? NVDA wants ARM in a desperate attempt to get sales growth positive. Sheesh.) Same for PFE? Maybe I'll take Buffett's advice and buy the SP500.
|
|
|
Pfizer
Mar 5, 2024 23:50:28 GMT
Post by anovice on Mar 5, 2024 23:50:28 GMT
|
|
|
Pfizer
Mar 6, 2024 22:27:51 GMT
Post by bb2 on Mar 6, 2024 22:27:51 GMT
PFE up over 4% today on an ADC for child leukemia, . 3100 kids/yr diagnosed. 42% complete remission and median 8.2 month remission. Just as I was reading about how poorly ADCs achieve CR.
|
|
|
Post by anitya on Mar 11, 2024 19:39:08 GMT
Do not see any news but stock price up by 4%. do u see any news?
|
|
|
Pfizer
Mar 12, 2024 1:09:54 GMT
Post by win1177 on Mar 12, 2024 1:09:54 GMT
Do not see any news but stock price up by 4%. do u see any news? Couldn’t find any specific news, several reports about new cancer drugs offering improved long term outlook. Maybe it’s just so “oversold” people are finally “waking up” to the value proposition??? Win
|
|
|
Post by uncleharley on Mar 12, 2024 1:31:36 GMT
The daily chart for PFE indicates that the price bottomed out in mid-December of last year. Since then, trading volume has increased significantly while the price has been consolidating in a rather tight trading range suggesting that the stock has been accumulated by a or several very smart traders. The accumulation/distribution line suggests the same thing. The breakout from the trading range that we have witnessed today, suggests that there is no more stock available at the current price. While the specific reason for the accumulation remains a mystery, one could look at any news that became published in mid-December for clues.
|
|
|
Pfizer
Mar 12, 2024 2:10:06 GMT
Post by howaya on Mar 12, 2024 2:10:06 GMT
Do not see any news but stock price up by 4%. do u see any news? Couldn’t find any specific news, several reports about new cancer drugs offering improved long term outlook. Maybe it’s just so “oversold” people are finally “waking up” to the value proposition??? Win People, or algos?
|
|
|
Post by anitya on Mar 12, 2024 2:21:33 GMT
Do not see any news but stock price up by 4%. do u see any news? Couldn’t find any specific news, several reports about new cancer drugs offering improved long term outlook. Maybe it’s just so “oversold” people are finally “waking up” to the value proposition??? Win 4% daily moves up or down on no news are supposed to happen for AI stocks or GLP stocks not for stocks like PFE. Let us see where this leads us.
|
|
|
Pfizer
Mar 12, 2024 17:32:10 GMT
Post by bb2 on Mar 12, 2024 17:32:10 GMT
Maybe the Adcetris trial result got leaked. Today the news came out.
Still waiting for a lower price. ADC tech is being chased by so many, so there must be something there and SeaGen seems to be the leader. Still, an estimate of $10B in sales from Seagen by 2030 doesn't seem huge for a $43B acquisition. But then, maybe more will come from it. PFE mentions the div 3 times on the last call and says outright that it's a priority. Like unclecharley says, strength lately. Long term, not so much. If I didn't already own it, I'd be more inclined to make a buy and hold here, not nitpicking about a buck or two.
DOwntown Josh Brown jump today.
|
|
|
Pfizer
Mar 12, 2024 18:42:30 GMT
Post by anitya on Mar 12, 2024 18:42:30 GMT
"DOwntown Josh Brown jump today."
Jump into or out of it?
|
|
|
Pfizer
Mar 12, 2024 19:27:59 GMT
Post by bb2 on Mar 12, 2024 19:27:59 GMT
In. CNBC around 12:47 ET. Off the low. Still negative for the day though, so far, so yea, not a huge jump.
|
|
|
Pfizer
Apr 18, 2024 20:13:36 GMT
Post by anitya on Apr 18, 2024 20:13:36 GMT
sold FSPHX from investing account and bought equivalent amount of PFE in the trading account.
PFE is a classic case of no touch today as its today's low and closing prices are lower than Yesterday's corresponding prices.
The last insider buy in this stock was on December 15.
|
|
|
Pfizer
May 16, 2024 10:41:58 GMT
via mobile
Post by chang on May 16, 2024 10:41:58 GMT
|
|